Active Biotech AB AI Stock Analysis
Want to see SE:ACTI full AI Analyst Report?
Active Biotech AB (ACTI) AI Stock Analysis
Active Biotech AB
(Nasdaq OMX AB:ACTI)
The score is primarily constrained by weak financial performance—zero revenue with ongoing losses and negative operating/free cash flow—despite improving loss and cash-burn trends and very low leverage. Technicals also lean bearish with the stock below key longer-term moving averages and a slightly negative MACD, while valuation is limited by a negative P/E and no provided dividend yield.
Active Biotech AB (ACTI) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 91.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 57.08K
- Price to Earnings (P/E)
- -5.1
- Beta (1Y)
- 0.11
- Revenue Growth
- ―
- EPS Growth
- 51.09%
- Country
- Sweden
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Active Biotech AB Business Overview & Revenue Model
Company Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which...
How the Company Makes Money
Active Biotech AB’s ability to generate revenue is primarily linked to the monetization of its drug development pipeline rather than product sales. Typical revenue sources for a clinical-stage biotech include (1) out-licensing or partnering its drug...
Active Biotech AB Financial Statement Overview
Summary
Financial quality is weak: revenue is zero across periods and profitability is deeply negative (EBIT/EBITDA/net income all negative). Losses and cash burn are improving versus prior years, and leverage is very low, but operating and free cash flow remain consistently negative and equity has declined in the latest period—raising ongoing funding/dilution risk.
Income Statement
6Very NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1.60M | -1.60M | -1.64M | -1.68M | -1.49M | -1.28M |
| EBITDA | -32.70M | -36.00M | -38.26M | -43.89M | -56.67M | -48.52M |
| Net Income | -33.60M | -37.30M | -39.40M | -45.80M | -58.69M | -49.88M |
Balance Sheet | ||||||
| Total Assets | 47.90M | 70.20M | 43.20M | 44.05M | 51.01M | 56.80M |
| Cash, Cash Equivalents and Short-Term Investments | 43.90M | 65.10M | 27.40M | 36.22M | 41.80M | 53.13M |
| Total Debt | 100.00K | 1.74M | 3.18M | 4.54M | 6.04M | 986.00K |
| Total Liabilities | 10.70M | 14.60M | 11.13M | 13.38M | 16.49M | 10.13M |
| Stockholders Equity | 37.20M | 55.60M | 32.07M | 30.67M | 34.51M | 46.67M |
Cash Flow | ||||||
| Free Cash Flow | -31.40M | -32.40M | -40.40M | -45.74M | -55.09M | -46.17M |
| Operating Cash Flow | -31.40M | -32.40M | -40.40M | -45.74M | -54.85M | -46.17M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -245.00K | 0 |
| Financing Cash Flow | 58.50M | 70.10M | 31.60M | 40.16M | 43.76M | 73.09M |
Active Biotech AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Negative. The current price of 3.60 is above the 20-day moving average (MA) of 3.55, below the 50-day MA of 3.87, and below the 200-day MA of 5.07, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.20 is Neutral, neither overbought nor oversold. The STOCH value of 26.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACTI.
Active Biotech AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:HNSA53Neutral
SE:ONCO46Neutral- SE:ACTI45Neutral
SE:SYNACT44Neutral
SE:BINV43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CANTA | 83Outperform | SEK 415.59M | 2.10 | 63.09% | ― | ― | ― |
| SE:HNSA | 53Neutral | SEK 3.96B | -5.69 | ― | ― | -3.57% | 8.84% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:ONCO | 46Neutral | SEK 772.99M | -2.79 | ― | ― | 65.37% | 43.28% |
| SE:ACTI | 45Neutral | SEK 91.08M | -5.14 | -85.07% | ― | ― | 51.09% |
| SE:SYNACT | 44Neutral | SEK 857.83M | -8.05 | -60.58% | ― | ― | 14.35% |
| SE:BINV | 43Neutral | SEK 201.36M | -0.41 | -128.54% | ― | -83.67% | -50.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACTI | Active Biotech AB | 3.60 | -2.70 | -42.86% | |
| SE:HNSA | Hansa Biopharma | 44.76 | 17.80 | 66.02% | |
| SE:BINV | BioInvent International AB | 3.02 | -28.18 | -90.32% | |
| SE:ONCO | Oncopeptides AB | 1.76 | -3.45 | -66.21% | |
| SE:SYNACT | SynAct Pharma AB | 15.06 | -6.69 | -30.76% | |
| SE:CANTA | Cantargia AB | 1.43 | -2.03 | -58.61% |
Active Biotech AB Corporate Events
Active Biotech Clears First Safety Cohort in Tasquinimod Myelofibrosis Trial
Active Biotech has reported that the first cohort of three patients treated under an amended protocol in the European Phase Ib/II HOVON 172 MF study of tasquinimod in myelofibrosis has completed a six-week safety evaluation. One serious adverse event...
Active Biotech Wins Japanese Patent for Laquinimod Eye Treatment, Bolstering Global IP Strategy
Active Biotech has secured a key patent in Japan for an ophthalmic eye-drop formulation of its clinical candidate laquinimod, designed to deliver the drug to the posterior parts of the eye for treating severe inflammatory conditions such as non-infec...
Active Biotech Deepens U.S. Ties to Advance Tasquinimod in Myelofibrosis
Active Biotech has expanded its U.S. collaboration by signing a new agreement with the Icahn School of Medicine at Mount Sinai, part of the Myeloproliferative Neoplasms Research Consortium, to support development of its drug candidate tasquinimod for...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026